糖尿病性心肌病：一篇教育性综述。
Diabetic cardiomyopathy: an educational review.
作者信息
Xiao Su-Lee, Bober Emilia, Kassianides Xenophon, Medici Francesco, Xiao Han B
机构信息
Specialist Registrar (ST5) Geriatric Medicine Charing Cross Hospital, Fulham Palace Road, London W6 8RF.
Foundation Year 1 Doctor Northwick Park Hospital, Watford Road, Harrow, Middlesex, HA1 3UJ.
出版信息
Br J Cardiol. 2023 Jun 13;30(2):18. doi: 10.5837/bjc.2023.018. eCollection 2023.
Abstract
This educational review provides information about the epidemiology of diabetes and heart failure (diabetic cardiomyopathy) and the challenges in diagnosis and screening. Details on how to investigate patients with imaging and other modalities are discussed, as well as an update regarding the efficacy and safety of novel agents for treatment of diabetic cardiomyopathy.
摘要
本教育综述提供了有关糖尿病和心力衰竭（糖尿病性心肌病）的流行病学信息以及诊断和筛查方面的挑战。文中讨论了如何使用影像学和其他方法对患者进行检查的细节，以及关于治疗糖尿病性心肌病的新型药物的疗效和安全性的最新情况。
相似文献
1
Diabetic cardiomyopathy: an educational review.糖尿病性心肌病：一篇教育性综述。
Br J Cardiol. 2023 Jun 13;30(2):18. doi: 10.5837/bjc.2023.018. eCollection 2023.
2
Diabetic cardiomyopathy.糖尿病性心肌病。
Rev Clin Esp (Barc). 2022 Feb;222(2):100-111. doi: 10.1016/j.rceng.2019.10.012. Epub 2020 Oct 23.
3
Diabetic cardiomyopathy: pathophysiology and clinical features.糖尿病心肌病：病理生理学和临床特征。
Heart Fail Rev. 2013 Mar;18(2):149-66. doi: 10.1007/s10741-012-9313-3.
4
Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.糖尿病性心肌病：导致这一临床实体的机制更新。
Circ Res. 2018 Feb 16;122(4):624-638. doi: 10.1161/CIRCRESAHA.117.311586.
5
Diabetic cardiomyopathy.糖尿病性心肌病
Rev Clin Esp. 2020 Feb 24. doi: 10.1016/j.rce.2019.10.013.
6
Diabetic cardiomyopathy - A comprehensive updated review.糖尿病心肌病——全面更新的综述。
Prog Cardiovasc Dis. 2019 Jul-Aug;62(4):315-326. doi: 10.1016/j.pcad.2019.03.003. Epub 2019 Mar 25.
7
Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies.临床方法治疗糖尿病性心肌病：人类研究综述。
Curr Med Chem. 2018;25(13):1510-1524. doi: 10.2174/0929867324666170705111356.
8
Prevalence and clinical characteristics of diabetic cardiomyopathy in patients with acute heart failure.糖尿病心肌病在急性心力衰竭患者中的患病率及临床特征。
Nutr Metab Cardiovasc Dis. 2024 May;34(5):1325-1333. doi: 10.1016/j.numecd.2023.12.013. Epub 2023 Dec 19.
9
Morphological characteristics in diabetic cardiomyopathy associated with autophagy.糖尿病心肌病中与自噬相关的形态学特征。
J Cardiol. 2021 Jan;77(1):30-40. doi: 10.1016/j.jjcc.2020.05.009. Epub 2020 Sep 6.
10
The diabetic cardiomyopathy.糖尿病性心肌病。
Acta Diabetol. 2011 Sep;48(3):173-81. doi: 10.1007/s00592-010-0180-x. Epub 2010 Mar 3.
本文引用的文献
1
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.糖尿病对钠-葡萄糖共转运蛋白 2 抑制剂肾脏结局影响的荟萃分析：大型安慰剂对照试验的协作荟萃分析。
Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6.
2
Remission of type 2 diabetes and improved diastolic function by combining structured exercise with meal replacement and food reintroduction among young adults: the RESET for REMISSION randomised controlled trial protocol.通过结合结构化运动、代餐和食物再引入来缓解 2 型糖尿病并改善年轻成年人的舒张功能：RESET 缓解试验的随机对照试验方案。
BMJ Open. 2022 Sep 21;12(9):e063888. doi: 10.1136/bmjopen-2022-063888.
3
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.达格列净在射血分数不同的心力衰竭患者中的应用：来自 DAPA-HF 和 DELIVER 研究的患者水平汇总荟萃分析。
Nat Med. 2022 Sep;28(9):1956-1964. doi: 10.1038/s41591-022-01971-4. Epub 2022 Aug 27.
4
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.达格列净治疗射血分数轻度降低或保留的心力衰竭。
N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27.
5
Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus.糖尿病心肌病和心力衰竭患者的病理生理学和治疗。
Int J Mol Sci. 2022 Mar 25;23(7):3587. doi: 10.3390/ijms23073587.
6
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
J Am Coll Cardiol. 2022 May 3;79(17):e263-e421. doi: 10.1016/j.jacc.2021.12.012. Epub 2022 Apr 1.
7
GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events.胰高血糖素样肽-1受体激动剂与冠状动脉：从机制到事件
Front Pharmacol. 2022 Mar 8;13:856111. doi: 10.3389/fphar.2022.856111. eCollection 2022.
8
Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.在 2 型糖尿病中，使用 SGLT2 抑制剂、GLP-1 受体激动剂及其联合治疗进行心血管和心力衰竭事件的一级预防。
Diabetes Care. 2022 Apr 1;45(4):909-918. doi: 10.2337/dc21-1113.
9
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.GLP-1 受体激动剂和 SGLT-2 抑制剂对心脏结构和功能的影响：临床证据的叙述性综述。
Cardiovasc Diabetol. 2021 Sep 28;20(1):196. doi: 10.1186/s12933-021-01385-5.
10
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
Zotero 插件